Prevention of episodic migraines with topiramate: results from a non-interventional study in a general practice setting

Table 6 Number of patients with reported adverse events (AEs) during the whole study (safety-sample)

	Total
	All AEs		AEs with CR^a
	N	%	N	%
At least one AE^b	46	13.7	35	10.4
At least one AE from the following class^b
Paraesthesia	10	3.0	9	2.7
Dizziness	4	1.2	4	1.2
Diarrhea	5	1.5	4	1.2
Nausea	14	4.2	8	2.4
Fatigue	4	1.2	4	1.2
Vomiting	4	1.2	1	0.3

Listed are adverse events occurring in >3 patients in the total sample
^aAEs with possible, probable, or very probable causal relationship (CR) with topiramate as assessed by the investigator
^bMultiple events possible

ISSN: 1129-2377